FDA approves vorasidenib for IDH1/IDH2-mutant grade 2 glioma
Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
In the randomized, double-blind, placebo-controlled INDIGO trial, vorasidenib significantly delayed disease progression (by blinded independent review) and delayed the time to the next anticancer intervention, compared with placebo, in a…
Primary source cited
Last reviewed